GAJ - HEP DART 2009 Presentations





		HEP DART 2009 Frontiers in Drug Development for Viral Hepatitis to view the complete abstract book Selected Slide Presentations Click on the links below to view presentations. Satellite Mini-Symposium: Toward Curative Therapies for Hepatitis C IDX184 - A Novel, Liver-targeted, Once-a-day Nucleotide Prodrug for the Treatment of Chronic HCV Infection Douglas Mayers; Idenix Pharmaceuticals, Inc., USA Update on Nitazoxanide in the Treatment of Chronic Hepatitis C Emmet Keeffe; The Romark Institute for Medical Research and Stanford University Medical Center, USA Nucleosides: Resistance, Genotypes, and Combinations David Nelson; University of Florida, USA Global Burden of Hepatitis Viruses, Natural History and Management State of the Art Presentation The Future Burden of Chronic Liver Disease and Global Opportunities for Therapeutic Interventions Brian McMahon; Alaska Native Medical Center and Alaska Native Tribal Health Consortium, USA Magnitude of Hepatitis Infection in Egypt and Africa Mostafa Mohamed; Ain Shams University, Egypt Review of the HCC Epidemic Hashem El-Serag; Baylor College of Medicine/Michael E. DeBakey VA Medical Center, USA Hepatitis E: One Virus, Many Faces Kenneth Sherman; University of Cincinnati College of Medicine, USA Discoveries and Advances in HCV Basic Research State of the Art Presentation The Long and Winding Road Leading to the Discovery of HCV Michael Houghton; Epiphany Biosciences, USA Insights into NS5A: A New Emerging Drug Target Timothy Tellinghuisen; The Scripps Research Institute, USA New Targets I: Cellular Systems and Infectious Models State of the Art Presentation Understanding Stat-C by Using Cell Culture Models Ralf Bartenschlager; University of Heidelberg, Germany HCV Management: Looking into the Crystal Ball HCV Treatment, Screening and Monitoring: 2009-2012 Jean-Michel Pawlotsky; Henri Mondor University Hospital, France HCV Treatment, Screening and Monitoring: 2012-2015 David Nelson; University of Florida, USA HCV Treatment, Screening and Monitoring: 2015 and Beyond Adrian Di Bisceglie; Saint Louis University School of Medicine, USA Emergence and Prevention of Viral Resistance State of the Art Presentation HBV Antiviral Drug Resistance: Prevention and Monitoring Anna Lok; University of Michigan Medical Center, USA An Update on HBV Resistance: The View From the Hepatocyte Stephen Locarnini; VIDRL, Australia Overview of HCV Resistance to Protease Inhibitors Philippe Halfon; Hôpital Ambroise Paré, France HCV Drug Resistance to Nucleoside and Non Nucleoside Polymerase Inhibitors: Potential Impact on HCV Therapies Isabel Nájera; Roche Palo Alto, USA A Retrospective Analysis of Tenofovir DF and Entecavir Combination Therapy in Patients with Chronic Hepatitis B (CHB) and Previous Treatment Failure (PTF) Robert Gish; CPMC, USA Clinical Trial Design Lessons Learned from Failed/Negative Studies in HCV Drug Development Paul Pockros; The Scripps Clinic, USA Planning Clinical Trials in Acute Hepatitis C (HCV) Douglas Dieterich; Mount Sinai School of Medicine, USA Oral Abstract Presentations I Selection of Hepatitis C Virus Resistant to Ribavirin Dino Feigelstock; CBER, Food and Drug Administration, USA Evidence that the Duck Hepatitis B Virus Covalently Closed Circular DNA is able to Survive Mitosis during Antiviral Therapy Allison Jilbert; University of Adelaide, Australia HCV Education Roundtable: Anticipating a New Clinical Paradigm for Hepatitis C Virus Treatment Overcoming Resistance Anticipating a New Clinical Paradigm for Hepatitis C Virus Treatment: Overcoming Resistance Veronica Miller; Forum for Collaborative HIV Research, USA A New Perspective on Resistance: Multiple Paths to SVR Resistance can be Overcome Veronica Miller; Forum for Collaborative HIV Research, USA New Targets II: Insights into Drug Mechanisms Ribavirin - Still Needed, but How Does It Work? Jordan Feld; Toronto Western Hospital Liver Centre, University of Toronto, Canada Anti-HCV Mechanisms of Action of Cyclophilin Inhibitors Philippe Gallay; The Scripps Research Institute, USA Attacking HBV Assembly: a General Target and a Specific Solution Adam Zlotnick; Indiana University, USA Optimizing Outcome of Therapeutics for Hepatitis Infections Can We Cure Hepatitis C without Interferon? Yves Benhamou; Hôpital Pitié-Salpêtrière, France Long Term Results of Pegylated Interferon Alfa 2a and Tenofovir for Hepatitis B Patrick Marcellin; Hôpital Beaujon, France The Case for Nucleosides as First Line Therapy for HBV Infection Jules Dienstag; Massachusetts General Hospital, USA Pharmacology and New Therapies for Hepatitis Infections Ending the PEG Interferon/Ribavirin Era in HCV Therapy: The Importance of Multiple Shots on Goal Robert Schooley; University of California San Diego, USA Pharmacology of IDX184, a Liver-targeted Nucleotide Prodrug for the Treatment of HCV David Standring; Idenix Pharmaceuticals, Inc., USA Oral Abstract Presentations II The Discovery and Early Development of the HCV NS3 Protease Inhibitor BMS-605339 Fiona McPhee; Bristol-Myers Squibb, USA Early Clinical Experience with BI201335, a Novel Hepatitis C Virus NS3-NS4A Serine Protease Inhibitor Donald Jensen; University of Chicago Medical Center, USA Assessment of Serum HCV-RNA at Week 12 Post-treatment is as Relevant as Week 24 to Predict SVR in HCV Patients Receiving Peginterferon plus Ribavirin Michelle Martinot-Peignoux; INSERM U-773, Université Paris VII, France Different Kinetics of Serum HBsAg Decline in HBeAg-positive vs HBeAg-negative Patients during 3 Years of Telbivudine Treatment in Chronic Hepatitis B (CHB) Karsten Wursthorn; Hannover Medical School, Germany Co-infections, Therapeutic Modalities and Regulatory Issues Public Health Challenges for HIV and Hepatitis C Coinfection Gregory Dore; University of New South Wales, Australia Treatment for Forgotten Population Mark Sulkowski; Johns Hopkins University, USA Regulatory Requirements for Combination Studies Richard Robson; Christchurch Clinical Studies Trust, New Zealand Immunological Approaches and Vaccines for Hepatitis Infections HCV Persistence and IFN Resistance Christoph Seeger; Fox Chase Cancer Center, USA Oral Abstract Presentations Efficacy, Safety, and Predictive Value of Early Virologic Response of albinterferon alfa-2b vs peginterferon alfa-2a in Treatment-Naïve Patients With Genotype 1 Chronic Hepatitis C Fred Poordad; Cedars-Sinai Medical Center, USA Liver Damage, Decompensation Fibrosis and Hepatocellular Carcinoma State of the Art Presentation Prevention of HCC in Hepatitis B Patients Using Antiviral Agents Yun-Fan Liaw; Chang Gung Memorial Hospital, Taiwan Cellular Evolution in Patients Chronically Infected with Hepatitis B Virus William Mason; Fox Chase Cancer Center, USA Management of Liver "Stiffness" and Hepatocellular Carcinoma (HCC) Masao Omata; University of Tokyo, Japan Hepatic Elastography for Measuring Liver Fibrosis Nezam Afdhal; Beth Israel Deaconess Medical Center, USA Biomarkers of Liver Injury for Hepatitis Clinical Trials: An Overview of Longitudinal Studies Thierry Poynard; Hôpital Pitié-Salpêtrière, France Can an Aberrant IgG be used as a Biomarker for Disease Progression? Timothy Block; Hepatitis B Foundation and Drexel University College of Medicine, USA Oral Abstract Presentations III MicroRNA: New Biomarkers in Chronic Liver Disease Hans Peter Dienes; University Hospital Cologne, Germany Late Breaker Oral Abstract Presentations SPC3649 Antagonizes the HCV Host Factor MicroRNA-122 in Chronically Infected Chimpanzees and Suppresses HCV RNA Accumulation Robert Lanford; Southwest Foundation for Biomedical Research, USA A Phase Ib Placebo-Controlled, Randomized Study of the Safety, Pharmacokinetics and Antiviral Activity of p7 Inhibitor BIT225 in Patients with Hepatitis C Virus (HCV) Infection Carolyn Luscombe; Biotron Limited, USA